Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31374378 | 0.83 | MAPK1 (0.49) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL7208909 | 0.83 | MAPK1 (0.49) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL28006025 | 0.77 | HSP90AA1 (0.44) | MEN1KMT2ALMNAMAPTMAPK1 | |
| Nitric Acid SCHEMBL20984111 | 0.76 | MEN1 (0.47) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL7209295 | 0.73 | TDP1 (0.41) | MEN1KMT2ATDP1ALDH1A1 | |
| Nitric Acid SCHEMBL9805652 | 0.72 | TSHR (0.48) | MEN1KMT2AMAPTHSP90AA1TDP1 | |
| SCHEMBL11568673 | 0.71 | MAPT (0.35) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL4772249 | 0.69 | RAB9A (0.48) | MEN1KMT2ALMNAMAPTTDP1 | |
| SCHEMBL4159994 | 0.69 | MEN1 (0.52) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL58157 | 0.68 | TDP1 (0.65) | MEN1KMT2AMAPTMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051967-B1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | NEOMED INST (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-8093402-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2011-06-09 | — | — | US | disclosed |
| US-7906654-B2 | (S)(-)-2-(7-chloro-6-fluoro-1H-benzimidazol-1-yl)-N-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide; treatment of pain; vanilloid receptor inhibitor; Antagonists maintain analgesic properties, but avoid pungency and neurotoxicity side effects of agonists | ASTRAZENECA AB (SE) | 2011-03-15 | — | — | US | disclosed |
| EP-2051967-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | AstraZeneca AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080221188-A1 | New Benzimidazole Derivatives | ASTRAZENECA R&D SODERTALJE (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008018827-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATMENT OF VALLINOID RECEPTOR TRPV1 RELATED DISORDERS | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | WO | disclosed |
| EP-0003881-A1 | Substituted phenylnitramines, their preparation and their application as fungicidal agents | AMERICAN CYANAMID COMPANY (US) | 1979-09-05 | — | — | EP | disclosed |
| US-4130645-A | Fungicidal phenylnitramines and new phenylnitramines | AMERICAN CYANAMID COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221188-A1 | New Benzimidazole Derivatives | OPRD1, OPRK1, SDHA | MEN1 4784/4885KMT2A 3662/4885LMNA 3359/4885 |
| US-20110137045-A1 | BENZIMIDAZOLE DERIVATIVES | OPRD1, OPRK1, SDHA | MEN1 4698/4885KMT2A 3789/4885LMNA 3182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.